Clinical trial
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
NCT00125918 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00125918 |
|---|---|
| Title | PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension |
| Official title | PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | ICOS Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | tadalafil, placebo |
| Enrollment | 406 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Aug 2, 2005 |
| Last update posted | Feb 21, 2008 |
| Countries | France, Italy, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: